Compare

Dare Bioscience, Inc. vs 60 Degrees Pharmaceuticals, Inc. vs Shattuck Labs, Inc. vs Neuphoria Therapeutics Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearDare Bioscience, Inc.
DARE
60 Degrees Pharmaceuticals, Inc.
SXTP
Shattuck Labs, Inc.
STTK
Neuphoria Therapeutics Inc.
NEUP
Year ended2025-12-312025-12-312025-12-312026-06-30
Revenue$1.03M$1.01M$1.00M$1.17M
Revenue growth (YoY)n/m+65.5%-82.5%-92.5%
Gross margin71.3% (computed)22.3%n/an/a
Operating marginn/m-771.6%n/mn/m
Net marginn/m-732.5%n/mn/m
Net income-$13.40M-$7.37M-$48.81M-$13.45M
EPS (Diluted)-$1.20-$11.73-$0.70-$3.06
Operating cash flow-$9.90M-$6.85M-$39.88M-$12.35M
Free cash flow-$10.29M-$6.99M-$39.95Mn/a
Cash & equivalents$24.71M$1.51M$54.19M$19.87M
Total assets$32.47M$5.37M$91.03M$28.71M
Total liabilities$29.63M$1.99M$8.64M$4.11M
Shareholders' equity$2.84M$3.46M$82.39M$24.60M
Return on year-end equity-471.4%-212.7%-59.2%-54.7%
Shares outstanding14.50M1.16M63.28M5.41M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearDare Bioscience, Inc.60 Degrees Pharmaceuticals, Inc.Shattuck Labs, Inc.Neuphoria Therapeutics Inc.
Latest$1.03M
Ended 2025-12-31
$1.01M
Ended 2025-12-31
$1.00M
Ended 2025-12-31
$1.17M
Ended 2026-06-30
1 year earlier$9.8K
Ended 2024-12-31
$607.6K
Ended 2024-12-31
$5.72M
Ended 2024-12-31
$15.65M
Ended 2025-06-30
2 years earlier$2.81M
Ended 2023-12-31
$253.6K
Ended 2023-12-31
$1.66M
Ended 2023-12-31
n/a
3 years earlier$10.00M
Ended 2022-12-31
$223.2K
Ended 2022-12-31
$652.0K
Ended 2022-12-31
n/a
4 years earlier$0
Ended 2021-12-31
n/a$30.02M
Ended 2021-12-31
n/a